Liraglutide
Also known as: Victoza, Saxenda
A once-daily GLP-1 receptor agonist approved for diabetes and weight management.
Overview
Liraglutide is a GLP-1 receptor agonist with 97% homology to native human GLP-1. An acyl group attachment enables albumin binding, extending its half-life to approximately 13 hours for once-daily dosing.
Mechanism of Action
Activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through hypothalamic signaling.
Pharmacokinetics
Peak concentration 8-12 hours post-injection. Half-life approximately 13 hours. Primarily metabolized endogenously.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Initiation
0.6 mg
Once daily
1 week
Starting dose
Titration
1.2 mg to 2.4 mg
Once daily
1 week each
Weekly increases
Maintenance
3.0 mg
Once daily
Ongoing
Weight management dose
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1SCALE trials demonstrated 8% mean weight loss at 3.0mg daily
- 2LEADER trial showed cardiovascular mortality benefit in T2D patients
- 3Effective in adolescent obesity treatment
- 4First GLP-1 agonist approved for weight management
Side Effects & Contraindications
Reported Side Effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
Contraindications
- MTC/MEN2 history
- Pregnancy
Safety Considerations
GI side effects common during titration. Same MTC/MEN2 warnings as other GLP-1 agonists.
Storage Requirements
Refrigerate at 2-8C
Scientific References
- 1